A 12-year-old boy was admitted to the paediatric ward with a 4-month history of worsening pain and bruising to his legs, which had resulted in a progressive reduction in his mobility. He initially had had difficulty weight bearing, which had then progressed further making him wheelchair bound. On examination, there was extensive bruising (figure 1) to his oedematous legs, worse on his right leg compared with his left. His background of autism and 15q13.3 deletion, along with maternal learning difficulties, made deciphering a clear history difficult. However, there was no account of trauma, and he had been afebrile throughout his illness. He had though lost 6 kg in weight but remained clinically stable. He was admitted to the ward for further assessment.Figure 1Clinical photograph showing bilateral bruises and swellings of the legs.Question 1What differentials should be considered?Question 2What investigation is more likely to suggest the diagnosis?Baseline bloods: full blood count—including platelets, albumin and coagulation.Extended bloods: vasculitis screen, erythrocyte Sedimentation Rate, endocrinopathies and iron studies.Doppler ultrasound calves.X-ray legs/hips.MRI tibia and fibula.Initial investigations showed a haemoglobin of 67 g/L, with mean cell volume of 76 fL. Platelet count and white cell counts, including differentials, were all within range. Infection markers, renal function tests, liver function tests and clotting screens were all normal. Leg X-rays were performed and showed no obvious fracture. However, there were some bone changes noted that had not been present 4 months prior during a previous presentation.USS Doppler of his calves were done, excluding deep vein thrombosis.Further investigations as to possible causes of his anaemia and other symptoms were then started, including rheumatology screens, haemaglobinpathy screens, endocrinopathies and viral screens. These results, along with vitamin D levels and bone profile, all came back normal. However, iron studies showed low serum iron and transferrin saturation. He had been empirically treated with a course of intravenous ceftriaxone on admission, which was subsequently stopped in view of lack of any evidence (clinically, radiologically or otherwise) of osteomyelitis, septic arthritis or other infective state.His behaviour on the ward, however, quickly raised some questions; in particular his detailed dietary history showed a very limited range, consisting solely of chicken nuggets, chips and pizza.Therefore, while awaiting results of any definite ‘cause’ of his immobility, his care was managed holistically. He was started on oral iron therapy and a strict dietary plan, including Ensure supplements. Physiotherapy was started, and various methods to encourage him to mobilise were commenced. His reluctance to engage with these 'treatments' initially caused problems, however through negotiation of ‘iPad time’ with compliance, they were slowly built up. Along with other professionals, the safeguarding team were also involved in his care at this point.Though a clear diagnosis was still unclear, he clinically improved. Oedema of his legs and bruising reduced, and he was able to mobilise a few steps further each day on the ward.Question 3What is the most likely action that would help confirm the diagnosis?Bone marrow biopsy.Full-body MRI.Complete nutritional history.Referral to tertiary orthopaedic centre.Answers can be found on page 02.
G540(P) Figure 1 Rate of Central line associated blood stream infection per 1000 central line days
Aim To assess blood vitamin D levels at time of cancer diagnosis in children, to supplement vitamin D where necessary, and reassess levels after 6 months of treatment. Methods Newly diagnosed children had vitamin D, calcium [Ca], phosphate [P04] and parathyroid hormone (PTH) levels checked. Vitamin D deficiency was defined as a serum 25-hydroxyvitamin D (25[OH]D) level of less than 50 nmol/L, and vitamin D insufficiency was defined as a 25[OH]D level of 50–75 nmol/L. Children with levels <50 nmol/L were given cholecalciferol (6000 units/day >10 years, 3000 units/day <10 years) while children with levels between 50 –75 nmol/L received a lower dose (2000 units/day >10 years, 1000 units/day <10 years). Vitamin D levels were rechecked after 6 months. Results Forty-four children (31 male, 13 female) aged between 4 to 19 years were studied. Twenty-six children were Caucasian and 18 were of Asian/African ethnicity. Only 16% [n = 7] of children had normal Vitamin D levels at diagnosis. The remaining 84% had either severe deficiency [n = 28; 64%] or insufficiency [n = 9; 20%]. Mean vitamin D levels in Caucasian children were 54 nmol/L compared to 35 nmol/L (p < 0.05) in African/Asian children. 50% [n = 13/26] of Caucasian children were considered vitamin D deficient vs. 78% [n = 14/18] of children of Asian or African ethnicity [p < 0.05] There was no seasonal variation in the mean vitamin D levels; 44.6 nmol/L in autumn/winter vs. 47.8 nmol/L in spring or summer. Of those with vitamin D < 50 nmol/L, 3 had serum PO4 <0.89 and high PTH levels. In 2 children, with vitamin D <75 nmol/L, Ca was <2.15 nmol/L. Of the six children who have had 6 months of vitamin D supplementation, levels have normalised in four children [5/7 required treatment doses], and improved but not normal levels in two children One child who had normal vitamin D level at diagnosis but at 6 months, has become deficient [vitamin D <50 nmol/L]. Conclusion Vitamin D plays an import part in bone metabolism and may also have a significant role in immune surveillance. The majority of our children were vitamin D deficient at diagnosis with significantly lower levels in African/Asian children. Derangement of PTH, calcium or phosphate was rare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.